Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $926.3 million.

  • Madrigal Pharmaceuticals' Cash & Current Investments rose 11.13% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 1.96%. This contributed to the annual value of $926.3 million for FY2024, which is 46.07% up from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Cash & Current Investments stood at $926.3 million, which was up 46.07% from $634.1 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Cash & Current Investments registered a high of $926.3 million during FY2024, and its lowest value of $270.3 million during FY2021.
  • In the last 3 years, Madrigal Pharmaceuticals' Cash & Current Investments had a median value of $634.1 million in 2023 and averaged $639.7 million.
  • In the last 5 years, Madrigal Pharmaceuticals' Cash & Current Investments crashed by 35.28% in 2020 and then surged by 76.75% in 2023.
  • Madrigal Pharmaceuticals' Cash & Current Investments (Yearly) stood at $284.1 million in 2020, then dropped by 4.86% to $270.3 million in 2021, then spiked by 32.71% to $358.8 million in 2022, then skyrocketed by 76.75% to $634.1 million in 2023, then skyrocketed by 46.07% to $926.3 million in 2024.